{"id":"dalantercept-plus-sorafenib","phase":"phase_1","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"active","trials":["NCT02024087"],"aliases":["ACE-041"],"patents":[],"pricing":[],"modality":"Small molecule","timeline":[],"aiSummary":"","brandName":"Dalantercept plus sorafenib","companyId":"acceleron-pharma-inc-a-wholly-owned-subsidiary-of-merck-co-inc-rahway-nj-usa","mechanism":{"target":"ALK-1 (Activin receptor-like kinase 1) and multiple kinases (VEGFR, PDGFR, RAF)","novelty":"","modality":"Small molecule","drugClass":"","explanation":"Dalantercept is a soluble receptor fusion protein that binds BMP9 and BMP10, blocking ALK-1 signaling to inhibit angiogenesis. Sorafenib inhibits VEGFR, PDGFR, and RAF kinases. The combination aims to provide dual anti-angiogenic and anti-tumor effects through complementary mechanisms.","oneSentence":"Dalantercept inhibits ALK-1 signaling to disrupt tumor angiogenesis, while sorafenib blocks multiple kinases involved in tumor growth and blood vessel formation.","technicalDetail":""},"commercial":null,"_claudeStub":{"ts":1779123366,"model":"claude-sonnet-4-5-20250929"},"companyName":"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA","competitors":[{"name":"lenvatinib","brand":"Lenvima","company":"Eisai","rationale":"Multi-kinase inhibitor for hepatocellular carcinoma and renal cell carcinoma"},{"name":"cabozantinib","brand":"Cabometyx","company":"Exelixis","rationale":"Multi-kinase inhibitor targeting VEGFR for advanced renal cell carcinoma"},{"name":"regorafenib","brand":"Stivarga","company":"Bayer","rationale":"Multi-kinase inhibitor for hepatocellular carcinoma after sorafenib"}],"description":"Dalantercept plus sorafenib is an investigational combination therapy being developed by Acceleron Pharma (now part of Merck). Dalantercept is a fusion protein targeting the ALK-1 pathway, combined with sorafenib, a multi-kinase inhibitor, for potential treatment of advanced solid tumors.","genericName":"Dalantercept plus sorafenib","indications":{"approved":[{"status":"investigational","condition":"Hepatocellular carcinoma","patientPopulation":"Adult, advanced disease"},{"status":"investigational","condition":"Renal cell carcinoma","patientPopulation":"Adult, advanced disease"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"trialDetails":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"rwe":[],"genericFilers":[],"relatedDrugs":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":false,"score":2}}